Vered Caplan
CEO, President, & Director
Claimed by owner Orgenesis
Former names:
Converting Liver Cells into Insulin-producing Cells
Public on NASDAQ Mar, 2018
Orgenesis
www.proactiveinvestors.com
•
Dec 3, 2020
https://www.proactiveinvestors.com/companies/news/935582/orgenesis-leads-the-charge-at-an-exciting-time-for-cell-and-gene-therapy-935582.html
www.biopharma-reporter.com
•
Nov 17, 2020
Orgenesis CEO talks disruption: 'We are the Uber of the cell and gene therapy space'
www.proactiveinvestors.com
•
Feb 19, 2020
Orgenesis teams up with Johns Hopkins University to develop gene therapies with its POCare platform
www.globenewswire.com
•
Jun 17, 2019
Orgenesis Granted FDA Orphan Drug Designation for Autologous Insulin Producing Cells in the Treatment of Severe Hypoglycemia-Prone Diabetes Resulting from Total Pancreatectomy
www.globenewswire.com
•
Apr 30, 2019
Orgenesis Announces Planned Study to Confirm Suitability of Liver Cells as a Source for Personalized Cell Replacement Therapy for Insulin-Dependent Diabetic Patients
www.globenewswire.com
•
Apr 22, 2019
Orgenesis Announces Collaboration Agreement with Columbia University to Develop Cellular Vaccination Product Platform for Pancreatic, Hepatic and Cholangiocarcinoma Cancers
www.globenewswire.com
•
Apr 11, 2019
Orgenesis Announces Collaboration and License Agreement for Exosome-Related Technologies with ExcellaBio
www.globenewswire.com
•
Apr 4, 2019
Orgenesis Announces Collaboration with Digilab to Develop Industrial 3D Printing Capability for Cellular Structures and Tissues for Clinical Use
www.globenewswire.com
•
Apr 3, 2019
Orgenesis Announces Publication of an Independent Study "The Role of The Vasculature Niche on Insulin Producing Cells Generated by Transdifferentiation of Adult Human Liver Cells" in the Stem Cell Research and Therapy Journal
www.globenewswire.com
•
Mar 28, 2019
Orgenesis Signs Master Service and Joint Venture Agreement with TheraCell Advanced Biotechnology for the Development of Cell and Gene Therapies
www.globenewswire.com
•
Mar 25, 2019
Orgenesis Subsidiary Masthercell Global Announces Plans to Establish New Facility for Cell and Gene Therapy Commercial Manufacturing
www.globenewswire.com
•
Feb 5, 2019
Orgenesis Announces the Opening of New Offices and Laboratories at Accessia Pharma in Liège, Belgium to Support its Point of Care Cellular Therapy Platform
www.globenewswire.com
•
Jan 25, 2019
Orgenesis Announces U.S. Expansion of Masthercell Global Subsidiary
www.globenewswire.com
•
Jan 22, 2019
Orgenesis Subsidiary Atvio Biotech to Present at Phacilitate Leaders World 2019 Conference
www.globenewswire.com
•
Jan 3, 2019
Orgenesis CEO Selected to Participate in Cell and Gene Therapy Workshop at Biotech Showcase 2019 in California
globenewswire.com
•
Dec 18, 2018
Orgenesis Announces Collaboration with MangoGen Pharma for Advanced Gene Delivery Platform
www.proactiveinvestors.com
•
Dec 12, 2018
https://www.proactiveinvestors.com/companies/news/211072/orgenesis-seals-pact-with-ben-gurion-university-to-develop-dissolvable-carriers-for-cell-culturing-211072.html
www.proactiveinvestors.com
•
Nov 2, 2018
Orgenesis CEO says companies looking for ways to get costs of medicine down
www.thepharmaletter.com
•
Oct 22, 2018
Orgenesis optimistic that Hemogenyx deal will 'transform bone marrow transplantation'
in.bgu.ac.il
•
Aug 27, 2018
Orgenesis Announces Collaboration with Ben-Gurion University to Develop and Commercialize a Novel Scaffold Technology for Cell Transplantation
globenewswire.com
•
Apr 30, 2018
Orgenesis Appoints Professor Lorenzo Piemonti to Scientific Advisory Board
www.globes.co.il
•
Dec 23, 2015
Israeli cell therapy co Orgenesis raises $10m
www.news-medical.net
•
Nov 26, 2014
Orgenesis receives €2.015 million grant to develop potential cure for Type 1 Diabetes
www.benzinga.com
•
Nov 3, 2014
How Orgenesis Hopes To Cure Type 1 Diabetes
newatlas.com
•
Aug 26, 2014
New diabetes treatment would turn liver cells into insulin-producers
About
Orgenesis is a vertically integrated biopharmaceutical company developing and manufacturing cell-therapy solutions. The company's MaSTherCell subsidiary is a global contract development and manufacturing organization. Through MaSTherCell, Orgenesis is able to deliver optimized process industrialization capacities to cell-therapy companies and speed up the arrival of these therapies onto the market.
MaSTherCell's customers include many pharmaceutical and biotechnology companies, as well as research institutions and hospitals involved in cell therapy.
Orgenesis is also developing its own proprietary cell therapies. Through its subsidiary, Orgenesis is developing solutions in the process of transdifferentiation (or cell reprogramming), whereby an adult cell is converted into another type of cell with a distinct phenotype and function. Orgenesis has utilized its proprietary technology and processes to successfully reprogram human liver cells into fully functional, glucose-responsive insulin-producing cells.
In June 2019, Orgenesis was granted an FDA orphan drug designation for its autologous insulin-producing cells.
MaSTherCell's customers include many pharmaceutical and biotechnology companies, as well as research institutions and hospitals involved in cell therapy.
Orgenesis is also developing its own proprietary cell therapies. Through its subsidiary, Orgenesis is developing solutions in the process of transdifferentiation (or cell reprogramming), whereby an adult cell is converted into another type of cell with a distinct phenotype and function. Orgenesis has utilized its proprietary technology and processes to successfully reprogram human liver cells into fully functional, glucose-responsive insulin-producing cells.
In June 2019, Orgenesis was granted an FDA orphan drug designation for its autologous insulin-producing cells.
Primary Sector
Life Sciences & HealthTech
Products
POCare
Geographic markets
Israel, United States, South Korea, Belgium
Funding
Total Funding
$28.2M
Market Cap
$29.88M
Last Funding
Undisclosed
Funding Stage
Total Rounds
5
Investors
1
News
(25)
www.proactiveinvestors.com
•
Dec 3, 2020
https://www.proactiveinvestors.com/companies/news/935582/orgenesis-leads-the-charge-at-an-exciting-time-for-cell-and-gene-therapy-935582.html
www.biopharma-reporter.com
•
Nov 17, 2020
Orgenesis CEO talks disruption: 'We are the Uber of the cell and gene therapy space'
www.proactiveinvestors.com
•
Feb 19, 2020
Orgenesis teams up with Johns Hopkins University to develop gene therapies with its POCare platform
www.globenewswire.com
•
Jun 17, 2019
Orgenesis Granted FDA Orphan Drug Designation for Autologous Insulin Producing Cells in the Treatment of Severe Hypoglycemia-Prone Diabetes Resulting from Total Pancreatectomy
www.globenewswire.com
•
Apr 30, 2019
Orgenesis Announces Planned Study to Confirm Suitability of Liver Cells as a Source for Personalized Cell Replacement Therapy for Insulin-Dependent Diabetic Patients
www.globenewswire.com
•
Apr 22, 2019
Orgenesis Announces Collaboration Agreement with Columbia University to Develop Cellular Vaccination Product Platform for Pancreatic, Hepatic and Cholangiocarcinoma Cancers
www.globenewswire.com
•
Apr 11, 2019
Orgenesis Announces Collaboration and License Agreement for Exosome-Related Technologies with ExcellaBio
www.globenewswire.com
•
Apr 4, 2019
Orgenesis Announces Collaboration with Digilab to Develop Industrial 3D Printing Capability for Cellular Structures and Tissues for Clinical Use
www.globenewswire.com
•
Apr 3, 2019
Orgenesis Announces Publication of an Independent Study "The Role of The Vasculature Niche on Insulin Producing Cells Generated by Transdifferentiation of Adult Human Liver Cells" in the Stem Cell Research and Therapy Journal
www.globenewswire.com
•
Mar 28, 2019
Orgenesis Signs Master Service and Joint Venture Agreement with TheraCell Advanced Biotechnology for the Development of Cell and Gene Therapies
www.globenewswire.com
•
Mar 25, 2019
Orgenesis Subsidiary Masthercell Global Announces Plans to Establish New Facility for Cell and Gene Therapy Commercial Manufacturing
www.globenewswire.com
•
Feb 5, 2019
Orgenesis Announces the Opening of New Offices and Laboratories at Accessia Pharma in Liège, Belgium to Support its Point of Care Cellular Therapy Platform
www.globenewswire.com
•
Jan 25, 2019
Orgenesis Announces U.S. Expansion of Masthercell Global Subsidiary
www.globenewswire.com
•
Jan 22, 2019
Orgenesis Subsidiary Atvio Biotech to Present at Phacilitate Leaders World 2019 Conference
www.globenewswire.com
•
Jan 3, 2019
Orgenesis CEO Selected to Participate in Cell and Gene Therapy Workshop at Biotech Showcase 2019 in California
globenewswire.com
•
Dec 18, 2018
Orgenesis Announces Collaboration with MangoGen Pharma for Advanced Gene Delivery Platform
www.proactiveinvestors.com
•
Dec 12, 2018
https://www.proactiveinvestors.com/companies/news/211072/orgenesis-seals-pact-with-ben-gurion-university-to-develop-dissolvable-carriers-for-cell-culturing-211072.html
www.proactiveinvestors.com
•
Nov 2, 2018
Orgenesis CEO says companies looking for ways to get costs of medicine down
www.thepharmaletter.com
•
Oct 22, 2018
Orgenesis optimistic that Hemogenyx deal will 'transform bone marrow transplantation'
in.bgu.ac.il
•
Aug 27, 2018
Orgenesis Announces Collaboration with Ben-Gurion University to Develop and Commercialize a Novel Scaffold Technology for Cell Transplantation
globenewswire.com
•
Apr 30, 2018
Orgenesis Appoints Professor Lorenzo Piemonti to Scientific Advisory Board
www.globes.co.il
•
Dec 23, 2015
Israeli cell therapy co Orgenesis raises $10m
www.news-medical.net
•
Nov 26, 2014
Orgenesis receives €2.015 million grant to develop potential cure for Type 1 Diabetes
www.benzinga.com
•
Nov 3, 2014
How Orgenesis Hopes To Cure Type 1 Diabetes
newatlas.com
•
Aug 26, 2014
New diabetes treatment would turn liver cells into insulin-producers
The Team
(2)
VC
EF
Evan Fishman
CFO
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
Undisclosed
Mar 2018
Stock Exchange
NASDAQ
Valuation
Undisclosed
Undisclosed
Private Equity Funding
Undisclosed Round
$3M
Dec 2013
1 Investors
$3M
Debt Financing
$10M
Dec 2015
$10M
Non-Equity Funding
Grant
$2.4M
Nov 2014
1 Grantors
$2.4M
Grant
$12.8M
Feb 2017
1 Grantors
$12.8M
Others
Academic Techonology
Jan 2008
undefined
Using Transdifferentiation for diabetes treatment
Academic Techonology
Aug 2018
undefined
A Novel Platform for Transplantation Devices
Media gallery
(3)
Locations
Israel
Pinhas Sapir St 8, Ness Ziona, Israel
Offices Abroad
20271 Goldenrod Lane, Germantown, MD, USA
Locations
Israel
Pinhas Sapir St 8, Ness Ziona, Israel
Offices Abroad
20271 Goldenrod Lane, Germantown, MD, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,